LPL expression has been shown to be a prognostic predictor in Chronic lymphocytic leukemia. In this haematological disorder, LPL appears to provide fatty acids as an energy source to malignant cells. Thus, elevated levels of LPL mRNA or protein are considered to be indicators of poor prognosis. Interactions Lipoprotein lipase has been shown to interact with LRP1. It is also a ligand for α2M, GP330, and VLDL receptors. LPL has been shown to be a ligand for LRP2, albeit at a lower affinity than for other receptors; however, most of the LPL-dependent VLDL degradation can be attributed to the LRP2 pathway. In each case, LPL serves as a bridge between receptor and lipoprotein. While LPL is activated by ApoC-II, it is inhibited by ApoCIII. In other organisms The LPL gene is highly conserved across vertebrates. Lipoprotein lipase is involved in lipid transport in the placentae of live bearing lizards (Pseudemoia entrecasteauxii). Interactive pathway map References Further reading External links GeneReviews/NCBI/NIH/UW entry on Familial Lipoprotein Lipase Deficiency Gene therapy for lipoprotein lipase deficiency EC 3.1.1